Skip to content
Acting Auditions – Lifestyle
Author:
SAB Biotherapeutics, Inc.
SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress
April 15, 2026
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
March 17, 2026
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
March 10, 2026
←
Previous Page
1
2